Bavarian Nordic raises expectations after another EU monkeypox vaccine order

HERA, the EU’s health emergency preparedness agency, has doubled its order for the Danish drugmaker’s vaccine against monkeypox, and the company has subsequently upgraded its financial guidance for the seventh time this year.

Photo: Sven Hoppe/AP/Ritzau Scanpix

A new order for an additional 170,000 doses of Bavarian Nordic’s monkeypox vaccine, sold as Imvanex in the EU, from the European Health Emergency Preparedness and Response Authority, HERA, is enough for the Danish drugmaker to raise its full-year expectations again, a company press release reports.

Bavarian is now expecting revenue for the year to come to DKK 2.8–3bn (USD 372.6–399.2m), up from the previous DKK 2.7–2.9bn (USD 359.3–385.8m), while the operating deficit forecast (EBITDA) has been raised to a loss of DKK 200m (USD 26m) at the most, and break-even at best. Before today, the company had estimated EBITDA would total a loss of DKK 100–300m (USD 13.3–39.9m). The company’s year-end cash position is raised to DKK 1.7bn (USD 226.2m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs